These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 33613773)
21. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells. Li Y; Zhuo B; Yin Y; Han T; Li S; Li Z; Wang J Biochem Biophys Res Commun; 2017 Sep; 491(1):134-139. PubMed ID: 28711493 [TBL] [Abstract][Full Text] [Related]
22. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Zhao L; Dong A; Gu J; Liu Z; Zhang Y; Zhang W; Wang Y; He L; Qian C; Qian Q; Liu X Cancer Gene Ther; 2006 Nov; 13(11):1011-22. PubMed ID: 16799468 [TBL] [Abstract][Full Text] [Related]
23. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy. Cai Y; Liu X; Huang W; Zhang K; Liu XY Acta Biochim Biophys Sin (Shanghai); 2012 Jun; 44(6):535-43. PubMed ID: 22635106 [TBL] [Abstract][Full Text] [Related]
24. Synergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirus. Wang S; Shu J; Chen L; Chen X; Zhao J; Li S; Mou X; Tong X Onco Targets Ther; 2016; 9():6381-6388. PubMed ID: 27799786 [TBL] [Abstract][Full Text] [Related]
25. An oncolytic adenoviral vector of Smac increases antitumor activity of TRAIL against HCC in human cells and in mice. Pei Z; Chu L; Zou W; Zhang Z; Qiu S; Qi R; Gu J; Qian C; Liu X Hepatology; 2004 May; 39(5):1371-81. PubMed ID: 15122766 [TBL] [Abstract][Full Text] [Related]
26. One potential oncolytic adenovirus expressing Lipocalin-2 for colorectal cancer therapy. Xu B; Zheng WY; Feng JF; Huang XY; Ge HY Cancer Biother Radiopharm; 2013 Jun; 28(5):415-22. PubMed ID: 23464854 [TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Ma S; Qu W; Mao L; Zhu Z; Jia L; Zhao L; Zheng X Oncol Rep; 2012 May; 27(5):1443-50. PubMed ID: 22294034 [TBL] [Abstract][Full Text] [Related]
28. Augmentation of Docetaxel-Induced Cytotoxicity in Human PC-3 Androgen-Independent Prostate Cancer Cells by Combination With Four Natural Apoptosis-Inducing Anticancer Compounds. Ahmed IA; Hafiz S; van Ginkel S; Pondugula SR; Abdelhaffez AS; Sayyed HG; El-Aziz EAA; Mansour MM Nat Prod Commun; 2023 May; 18(5):. PubMed ID: 37292146 [TBL] [Abstract][Full Text] [Related]
29. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Xiao T; Fan JK; Huang HL; Gu JF; Li LY; Liu XY Cell Res; 2010 Mar; 20(3):367-78. PubMed ID: 19918267 [TBL] [Abstract][Full Text] [Related]
31. Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma. Yang C; Cao H; Liu N; Xu K; Ding M; Mao LJ Drug Des Devel Ther; 2016; 10():3755-3761. PubMed ID: 27895465 [TBL] [Abstract][Full Text] [Related]
32. Inhibition of prostate cancer DU145 cell growth with small interfering RNA targeting the SATB1 gene. Wang Q; Yang CS; Ma ZX; Chen JC; Zheng JN; Sun XQ; Wang JQ Exp Ther Med; 2018 Mar; 15(3):3028-3033. PubMed ID: 29599837 [TBL] [Abstract][Full Text] [Related]
33. The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer. Li Q; Xu J; He Z; Wen X; Wang F; Zhang P; Li J; Song B; Wang Q; Li R; Huang H Cancer Manag Res; 2019; 11():10125-10133. PubMed ID: 31819645 [TBL] [Abstract][Full Text] [Related]
34. Self-assembled albumin nanoparticles for combination therapy in prostate cancer. Lian H; Wu J; Hu Y; Guo H Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392 [TBL] [Abstract][Full Text] [Related]
35. Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells. Inamura SO; Ito H; Taga M; Tsuchiyama K; Hoshino H; Kobayashi M; Yokoyama O Anticancer Res; 2019 Oct; 39(10):5417-5425. PubMed ID: 31570436 [TBL] [Abstract][Full Text] [Related]
36. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605 [TBL] [Abstract][Full Text] [Related]
37. Optimization of the Administration Strategy for the Armed Oncolytic Adenovirus ZD55-IL-24 in Both Immunocompromised and Immunocompetent Mouse Models. Hu HJ; Liang X; Li HL; Wang HY; Gu JF; Sun LY; Xiao J; Hu JQ; Ni AM; Liu XY Hum Gene Ther; 2021 Dec; 32(23-24):1481-1494. PubMed ID: 34155929 [TBL] [Abstract][Full Text] [Related]
38. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438 [TBL] [Abstract][Full Text] [Related]
39. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Zheng JN; Pei DS; Mao LJ; Liu XY; Sun FH; Zhang BF; Liu YQ; Liu JJ; Li W; Han D Cancer Gene Ther; 2010 Jan; 17(1):28-36. PubMed ID: 19498459 [TBL] [Abstract][Full Text] [Related]
40. Oncolytic viro-chemotherapy exhibits antitumor effect in laryngeal squamous cell carcinoma cells and mouse xenografts. Wang Y; Wang B; Liang J; Cui C; Ying C; Huang F; Ma B; Zhou X; Chu L Cancer Manag Res; 2019; 11():3285-3294. PubMed ID: 31114365 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]